Rotterdam Criteria PCOS Calculator- Free Phenotype Classification and Diagnosis Tool

About This Rotterdam Criteria PCOS Phenotype Calculator

This Rotterdam Criteria PCOS calculator is designed for women of reproductive age, healthcare professionals, and medical students seeking to understand how polycystic ovary syndrome is diagnosed using the internationally recommended Rotterdam diagnostic framework. The tool assesses three cardinal features of PCOS, hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, and determines whether the diagnostic threshold of two or more criteria is met.

The calculator implements the 2003 Rotterdam Criteria as updated by the 2023 International Evidence-Based Guideline endorsed by 39 medical societies worldwide. It follows the diagnostic algorithm that requires at least two of three criteria after exclusion of mimicking conditions including thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia. The tool references current clinical standards including the updated 20-follicle ultrasound threshold and anti-Mullerian hormone as an alternative to ultrasound for PCOM detection in adults.

The interactive phenotype comparison table displays all four Rotterdam PCOS phenotypes (A through D) with their associated metabolic, insulin resistance, cardiovascular, and fertility risk profiles. The radar spider chart provides a multi-dimensional visualization of criteria coverage and derived risk factors. Together, these visualizations help users understand not just whether PCOS criteria are met, but which specific phenotype applies and what risk profile it carries, enabling more informed discussions with healthcare providers about personalized management strategies.

Rotterdam Criteria Calculator for PCOS: Complete Guide to Diagnosis, Phenotype Classification, and Clinical Assessment

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder affecting women of reproductive age, with an estimated prevalence of 6 to 20 percent depending on the diagnostic criteria applied. Despite its widespread impact on fertility, metabolic health, and psychological wellbeing, PCOS remains a clinical diagnosis of exclusion, meaning no single test can confirm it. The Rotterdam Criteria, established in 2003 by a joint consensus of the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), remain the most widely accepted and internationally endorsed framework for diagnosing PCOS. This calculator implements the Rotterdam diagnostic algorithm to help healthcare professionals and individuals understand how these criteria are applied.

The cornerstone of the Rotterdam approach is that a PCOS diagnosis requires the presence of at least two out of three cardinal features: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology (PCOM). Additionally, other conditions that mimic PCOS must be excluded before the diagnosis can be made. The 2023 International Evidence-Based Guideline further refined these criteria by introducing anti-Mullerian hormone (AMH) as an alternative to ultrasound for detecting PCOM in adults, while also simplifying the diagnostic pathway for cases where both hyperandrogenism and ovulatory dysfunction are already present.

Understanding the Rotterdam Criteria: Historical Context and Evolution

The diagnostic journey of PCOS has undergone significant transformation since the condition was first described by Stein and Leventhal in 1935. Initially characterized by bilaterally enlarged, polycystic-appearing ovaries identified during surgical examination, the understanding of PCOS has evolved considerably over eight decades of clinical research. The first formal attempt to standardize PCOS diagnosis came in 1990, when the National Institutes of Health (NIH) sponsored a conference that defined the condition as requiring both hyperandrogenism (clinical or biochemical) and chronic oligo-anovulation, with the exclusion of other known disorders.

The 1990 NIH criteria, while groundbreaking, created tension with European clinical practice, where ultrasound evidence of polycystic ovaries was considered the defining feature. This disagreement persisted until 2003, when 27 PCOS experts convened in Rotterdam, the Netherlands, at a conference co-sponsored by ESHRE and ASRM. The resulting “Rotterdam Criteria” broadened the phenotypic expression of PCOS by adding polycystic ovarian morphology as a third diagnostic criterion and requiring only two of three features for diagnosis. This expansion acknowledged the heterogeneous nature of the syndrome and increased estimated prevalence by as much as 50 percent compared to the earlier NIH definition.

In 2006, the Androgen Excess Society (AES) proposed a modification that reinstated hyperandrogenism as a mandatory diagnostic feature, effectively excluding phenotype D (ovulatory dysfunction plus PCOM without androgen excess). However, the 2012 NIH evidence-based methodology workshop and the landmark 2018 International Evidence-Based Guideline unanimously endorsed the broader Rotterdam Criteria while recommending explicit phenotype identification. The 2023 update of this international guideline, endorsed by 39 medical societies worldwide, further strengthened the Rotterdam framework by incorporating AMH as a diagnostic alternative to ultrasound and simplifying the algorithm for cases presenting with both hyperandrogenism and ovulatory dysfunction.

The Three Diagnostic Criteria Explained

Criterion 1: Hyperandrogenism (Clinical or Biochemical)

Hyperandrogenism is often considered the hallmark feature of PCOS and can manifest in two forms: clinical or biochemical. Clinical hyperandrogenism refers to visible signs of androgen excess, the most common being hirsutism, which is the growth of terminal (coarse, pigmented) hair in a male-pattern distribution. Hirsutism is typically assessed using the modified Ferriman-Gallwey (mFG) scoring system, which evaluates terminal hair growth across nine body regions (upper lip, chin, chest, upper abdomen, lower abdomen, upper arms, thighs, upper back, and lower back) on a scale of 0 to 4 each. A total score of 8 or above is generally considered indicative of clinically significant hirsutism, though this threshold varies across ethnic groups. For example, lower thresholds (as low as 4 to 6) may be appropriate for East Asian and some Southeast Asian populations, while higher thresholds may apply for women of Mediterranean descent.

Other clinical signs of androgen excess include moderate to severe acne (particularly persistent inflammatory acne that is unresponsive to standard topical treatments) and androgenic alopecia (female pattern hair loss characterized by diffuse thinning at the crown with preservation of the frontal hairline). The 2023 guideline emphasizes that hirsutism alone should be considered predictive of biochemical hyperandrogenism and may be sufficient as clinical evidence without additional hormonal testing in certain clinical scenarios.

Biochemical hyperandrogenism is defined as elevated circulating androgen levels. The most commonly measured markers include total testosterone, free testosterone (measured directly or calculated from total testosterone and sex hormone-binding globulin), and the free androgen index (FAI). Dehydroepiandrosterone sulfate (DHEA-S) and androstenedione may also be assessed. Unfortunately, there is no universally standardized testosterone assay, and reference ranges vary between laboratories, making consistent biochemical diagnosis challenging. The gold standard for testosterone measurement is liquid chromatography-tandem mass spectrometry (LC-MS/MS), though immunoassays remain more widely used in clinical practice.

Criterion 2: Ovulatory Dysfunction

Ovulatory dysfunction in the context of PCOS encompasses a spectrum from complete anovulation (absence of ovulation) to oligo-ovulation (infrequent or irregular ovulation). This is most commonly assessed through menstrual cycle history, as irregular menstrual cycles serve as a reliable clinical indicator of ovulatory dysfunction. The 2023 international guideline provides specific definitions based on time since menarche:

For adults (more than 3 years post-menarche to perimenopause): menstrual cycles shorter than 21 days or longer than 35 days, or fewer than 8 cycles per year, are considered irregular and suggestive of ovulatory dysfunction. Amenorrhea, defined as the absence of menstruation for 90 days or more, also qualifies. For adolescents within 1 to 3 years of menarche: cycles shorter than 21 days or longer than 45 days are considered irregular. Beyond 3 years post-menarche, adult criteria apply.

It is important to note that some women with PCOS may have apparently regular menstrual cycles (eumenorrhea) yet still experience anovulation. In these cases, serum progesterone measurement during the mid-luteal phase (approximately day 21 of a 28-day cycle) can confirm whether ovulation has occurred. A progesterone level below 3 to 5 ng/mL (10 to 16 nmol/L) during this window suggests anovulation. Serial ultrasound monitoring of follicular development can also be used but is more resource-intensive.

Criterion 3: Polycystic Ovarian Morphology (PCOM)

Polycystic ovarian morphology refers to the characteristic appearance of the ovaries on imaging, not the presence of ovarian “cysts” in the traditional pathological sense. The so-called cysts are actually immature follicles that have arrested in their development. The original 2003 Rotterdam ultrasound criteria defined PCOM as the presence of 12 or more follicles measuring 2 to 9 mm in diameter and/or an ovarian volume exceeding 10 mL in at least one ovary, using transvaginal ultrasound.

However, advances in ultrasound technology since 2003 have significantly improved imaging resolution, leading to higher follicle counts in normal women. This prompted a revision of the follicle count threshold. The 2018 and 2023 international guidelines updated the follicle number per ovary (FNPO) threshold to 20 or more follicles (measuring 2 to 9 mm) in at least one ovary when using ultrasound transducers with a frequency of 8 MHz or higher. The ovarian volume threshold of 10 mL or greater remains unchanged and can be used as an alternative, particularly when follicle counting is not feasible or with older ultrasound equipment.

A major advancement in the 2023 guideline is the formal inclusion of anti-Mullerian hormone (AMH) as an alternative to ultrasound for detecting PCOM in adults. AMH is a glycoprotein hormone produced by granulosa cells of small antral and preantral follicles. Women with PCOS typically have elevated AMH levels because of their increased number of small follicles. Meta-analyses supporting this recommendation demonstrated pooled sensitivity of 79 percent and specificity of 87 percent for AMH in diagnosing PCOS in adults. However, no universal AMH cutoff value has been established, as levels are influenced by age, body mass index, assay type, and ethnicity. AMH should not be used for PCOS diagnosis in adolescents due to overlap with normal pubertal physiology.

The Four PCOS Phenotypes Under Rotterdam Criteria

Because the Rotterdam Criteria require any two of three features, four distinct phenotypic combinations are possible. Identifying the specific phenotype has important implications for prognosis, metabolic risk assessment, and treatment planning. The 2012 NIH workshop explicitly recommended that all research studies and clinical documentation specify the PCOS phenotype.

Phenotype A represents the full classic presentation with all three features present. These women typically have the most severe metabolic disturbances, including the highest rates of insulin resistance, impaired glucose tolerance, dyslipidemia, and risk of type 2 diabetes. Phenotype A is the most common presentation in clinical referral populations, accounting for roughly 45 to 67 percent of diagnosed cases.

Phenotype B presents with hyperandrogenism and ovulatory dysfunction but without polycystic ovarian morphology on imaging. The metabolic profile of phenotype B is similar to phenotype A, with comparable levels of insulin resistance and cardiovascular risk factors. There is no clinically meaningful difference between phenotypes A and B in terms of endocrine or metabolic outcomes, and PCOM assessment does not alter management when both HA and OD are present.

Phenotype C describes women with hyperandrogenism and polycystic ovarian morphology who maintain regular ovulatory cycles. These women tend to have a milder metabolic profile than the anovulatory phenotypes, with lower rates of insulin resistance and often lower body mass index. However, they still demonstrate androgen excess and its associated dermatologic and reproductive implications.

Phenotype D, the non-hyperandrogenic form, includes women with ovulatory dysfunction and polycystic ovarian morphology but without evidence of androgen excess. This is the mildest phenotype in terms of metabolic risk, and some researchers have questioned whether it represents a distinct pathophysiology from the hyperandrogenic forms. The Androgen Excess Society criteria do not recognize phenotype D as PCOS. Despite this debate, the 2023 international guideline continues to include phenotype D within the Rotterdam diagnostic framework.

Conditions to Exclude Before Diagnosing PCOS

PCOS is a diagnosis of exclusion, meaning that other medical conditions capable of producing similar symptoms must be ruled out before the diagnosis can be made. The mandatory exclusion workup recommended by the 2023 international guideline includes thyroid dysfunction (assessed via TSH), hyperprolactinemia (serum prolactin), and non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone). Additional conditions to consider based on clinical presentation include Cushing syndrome, androgen-producing tumors (ovarian or adrenal), hypogonadotropic hypogonadism (particularly in women with very low body weight or intensive exercise), acromegaly, and primary ovarian insufficiency.

Overt virilization, characterized by deepening of the voice, clitoromegaly, increased muscle mass, and severe hirsutism with rapid onset, is not consistent with PCOS and should prompt urgent investigation for an androgen-producing tumor. Similarly, very high testosterone levels (typically above 150 to 200 ng/dL or 5.2 to 6.9 nmol/L) suggest a possible androgen-secreting neoplasm rather than PCOS.

Adolescent-Specific Diagnostic Considerations

Diagnosing PCOS in adolescents requires particular caution because many features of PCOS overlap with normal pubertal physiology. Irregular menstrual cycles are common in the first few years after menarche as the hypothalamic-pituitary-ovarian axis matures. Similarly, acne is highly prevalent during puberty, and polycystic ovarian morphology on ultrasound is frequently observed in healthy adolescent girls due to the naturally high antral follicle counts in this age group.

The 2023 international guideline explicitly recommends that in adolescents, both hyperandrogenism and ovulatory dysfunction must be present for a PCOS diagnosis. Ultrasound and AMH are not recommended for diagnostic purposes in this population due to poor specificity. If an adolescent presents with only one criterion, the diagnosis should be considered “at risk” rather than confirmed, with reassessment after full reproductive maturity (typically 8 years post-menarche). When PCOS features persist beyond 3 years after menarche, the adult diagnostic criteria may be applied.

Global Application and Population Considerations

While the Rotterdam Criteria were developed predominantly from studies in European and North American populations, they have been validated and applied across diverse populations worldwide. However, important variations exist in the expression of PCOS features across different ethnic groups. Hirsutism scoring thresholds, for example, differ significantly: the standard mFG threshold of 8 or higher applies primarily to Caucasian women, whereas lower thresholds (4 to 6) may be more appropriate for East Asian populations, and higher thresholds may apply for some Middle Eastern and Mediterranean populations where baseline terminal hair growth is more extensive.

Biochemical androgen levels also vary by ethnicity. Some studies suggest that the Framingham-derived cardiovascular risk calculations may underestimate risk in South Asian populations with PCOS, who tend to have higher rates of insulin resistance and metabolic syndrome at lower body mass indices compared to Caucasian women. Conversely, East Asian women with PCOS may have lower rates of hirsutism but higher rates of metabolic disturbances.

The World Health Organization and international endocrine societies recognize PCOS as a global health concern affecting women regardless of geographic location, ethnicity, or socioeconomic status. Healthcare providers worldwide are encouraged to apply the Rotterdam framework while being mindful of population-specific variations in symptom expression and risk profiles.

Associated Health Risks and Long-Term Implications

PCOS is not merely a reproductive disorder but a systemic condition with significant long-term health implications. Women with PCOS face increased risks of type 2 diabetes (3 to 7 times higher than the general population), metabolic syndrome, cardiovascular disease, non-alcoholic fatty liver disease, obstructive sleep apnea, and endometrial hyperplasia or carcinoma (due to chronic anovulation and unopposed estrogen exposure). The 2023 guideline strengthens the recommendation that individuals with PCOS should be recognized as having increased cardiovascular disease risk factors.

Psychological health is another critical dimension. Depression and anxiety are approximately 2.5 to 3 times more prevalent in women with PCOS compared to those without the condition. Body image concerns, eating disorders, and reduced quality of life are also significantly more common. The 2023 guideline recommends routine screening for depressive and anxiety symptoms using validated screening tools at diagnosis and at regular intervals thereafter.

Reproductive consequences extend beyond anovulatory infertility. Women with PCOS who become pregnant face higher risks of gestational diabetes, pregnancy-induced hypertension, preeclampsia, preterm birth, and cesarean delivery. Pre-conception optimization, including weight management, metabolic assessment, and folic acid supplementation, is particularly important for women with PCOS planning pregnancy.

Insulin Resistance and Metabolic Assessment

Insulin resistance is a central pathophysiological feature of PCOS, present in approximately 50 to 80 percent of affected women regardless of body weight. While not a diagnostic criterion, insulin resistance drives many of the metabolic complications associated with the syndrome. Elevated insulin levels stimulate ovarian androgen production, suppress hepatic SHBG synthesis (thereby increasing free testosterone), and contribute to the arrested follicular development characteristic of PCOM.

The 2023 guideline does not recommend routine insulin testing for PCOS diagnosis because there is no validated clinical test for detecting insulin resistance in the general population, and insulin assays are not standardized. Instead, the guideline recommends screening for metabolic consequences of insulin resistance through oral glucose tolerance testing (OGTT) or glycated hemoglobin (HbA1c), lipid panel, and blood pressure measurement. These assessments should be performed at diagnosis and repeated periodically, with greater frequency in higher-risk individuals (those with obesity, family history of diabetes, or phenotypes A and B).

Management Principles Based on Phenotype

Treatment of PCOS should be individualized based on the predominant symptoms, phenotype, and the woman’s reproductive goals. Lifestyle modification, including balanced nutrition and regular physical activity, is the first-line intervention for all PCOS phenotypes. Even modest weight loss of 5 to 10 percent in overweight or obese women can improve menstrual regularity, reduce androgen levels, and enhance insulin sensitivity.

For women not seeking pregnancy, combined oral contraceptive pills (COCPs) remain the primary pharmacological treatment for managing menstrual irregularity and clinical hyperandrogenism. Anti-androgen medications such as spironolactone, cyproterone acetate, or finasteride may be added for persistent hirsutism or acne. Metformin may be considered as adjunctive therapy for metabolic features, particularly in women with impaired glucose tolerance.

For women with PCOS-related infertility, lifestyle modification is again the first step, followed by ovulation induction with letrozole (now considered first-line over clomiphene citrate based on the 2023 guideline), gonadotropin therapy, or in vitro fertilization (IVF) for resistant cases. Laparoscopic ovarian drilling is considered a second-line surgical option when medical ovulation induction fails.

Modified Ferriman-Gallwey Scoring System

The modified Ferriman-Gallwey (mFG) scoring system is the most widely used clinical tool for quantifying hirsutism. It evaluates terminal hair growth in nine body areas, each scored from 0 (no terminal hair) to 4 (extensive terminal hair growth). The nine areas assessed are: upper lip, chin, chest, upper abdomen, lower abdomen, upper arms (both), thighs (both), upper back, and lower back. The maximum possible score is 36.

The scoring system has known limitations, including subjectivity in assessment (with documented inter-observer variability), influence of prior hair removal on scoring accuracy, ethnic variation in baseline terminal hair patterns, and patient discomfort with the examination of sensitive body areas. Research has shown that a simplified assessment focusing on just three body areas (chin, upper abdomen, and lower abdomen) can predict the total mFG score with approximately 86 percent accuracy and may be a practical screening alternative in busy clinical settings.

Anti-Mullerian Hormone (AMH) in PCOS Diagnosis

Anti-Mullerian hormone has emerged as a valuable biomarker in PCOS assessment. AMH is produced by granulosa cells of preantral and small antral follicles, and its serum levels correlate with the number of these follicles. Because women with PCOS have an increased pool of small antral follicles, their AMH levels are typically 2 to 4 times higher than those of women without the condition.

The 2023 international guideline now formally recommends that AMH can be used as an alternative to ultrasound for defining PCOM in adults. This recommendation is supported by meta-analyses demonstrating good diagnostic performance (pooled sensitivity of 79 percent and specificity of 87 percent in adults). AMH testing offers several practical advantages over ultrasound: it can be performed through a simple blood test at any point in the menstrual cycle (though some variation exists), does not require specialized imaging equipment or expertise, and avoids the need for transvaginal examination. However, important caveats remain: there is no internationally agreed-upon AMH cutoff value, AMH levels decline with age, and results can be influenced by obesity, hormonal contraceptive use, and the specific assay employed. AMH is not recommended for PCOS diagnosis in adolescents.

Limitations and Ongoing Debates

Despite their widespread adoption, the Rotterdam Criteria are not without controversy. Critics argue that the inclusion of phenotype D (ovulatory dysfunction plus PCOM without hyperandrogenism) may represent a different pathophysiology than hyperandrogenic PCOS, potentially leading to over-diagnosis. The Androgen Excess Society maintains that hyperandrogenism should be a mandatory diagnostic feature, effectively excluding phenotype D.

Recent genome-wide association studies (GWAS) have identified genetic subtypes of PCOS that do not align neatly with the Rotterdam phenotypic classification. Unsupervised clustering analyses have suggested that PCOS may be better characterized as two major subtypes, a “reproductive” subtype and a “metabolic” subtype, rather than the four phenotypes defined by the Rotterdam framework. This emerging genetic evidence may eventually inform a more biologically grounded classification system.

Additionally, the diagnosis of PCOS at the extremes of reproductive life, around menarche and approaching menopause, remains challenging because the diagnostic features naturally evolve with age. The 2023 guideline acknowledges that while initial PCOS diagnosis post-menopause is difficult, a historical or retrospective diagnosis based on clinical features and past documentation can be considered enduring and lifelong.

When to Seek Professional Evaluation

Women should consider seeking evaluation for PCOS if they experience persistent menstrual irregularity (cycles shorter than 21 days or longer than 35 days, or fewer than 8 cycles per year), unwanted facial or body hair growth, persistent acne beyond adolescence, unexplained weight gain (particularly central obesity), difficulty conceiving, or thinning hair on the scalp. A family history of PCOS, type 2 diabetes, or metabolic syndrome also increases risk and may warrant screening.

This calculator is designed to help individuals understand the Rotterdam diagnostic framework and assess which criteria they may meet based on their symptoms and clinical findings. It is intended as an educational tool and does not replace the clinical judgment of a qualified healthcare provider. A definitive PCOS diagnosis should always involve comprehensive clinical evaluation, appropriate laboratory testing, and imaging studies when indicated, performed and interpreted by trained medical professionals.

Frequently Asked Questions

Conclusion

The Rotterdam Criteria remain the cornerstone of PCOS diagnosis, providing a structured framework that accounts for the heterogeneous nature of this complex syndrome. From their establishment in 2003 through successive refinements in 2018 and 2023, these criteria have evolved to incorporate new evidence, including the role of anti-Mullerian hormone and updated ultrasound thresholds, while maintaining the fundamental principle that PCOS is defined by the presence of at least two of three cardinal features. Understanding the four resulting phenotypes allows for more nuanced risk stratification and personalized treatment planning. As research continues to uncover the genetic and pathophysiological underpinnings of PCOS, diagnostic criteria will likely continue to evolve. In the meantime, the Rotterdam framework, combined with thorough exclusion of mimicking conditions and identification of associated metabolic and psychological comorbidities, provides the best available approach to diagnosis and serves as the foundation for comprehensive patient care.